Stockscreener 앱 받기
2.27
1.34%
0.03
전일 마감가:
$2.24
열려 있는:
$2.3
하루 거래량:
172.44K
Relative Volume:
1.37
시가총액:
$17.12M
수익:
-
순이익/손실:
$-19.92M
주가수익비율:
-0.5314
EPS:
-4.2716
순현금흐름:
$-20.51M
1주 성능:
+16.41%
1개월 성능:
+39.26%
6개월 성능:
+78.74%
1년 성능:
-70.01%
1일 변동 폭
$2.08
$2.31
1주일 범위
$1.92
$2.31
52주 변동 폭
$1.06
$9.09
Biovie Inc Stock (BIVI) Company Profile
명칭
Biovie Inc
전화
775-888-3162
주소
680 W NYE LANE, CARSON CITY
Compare BIVI vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIVI
Biovie Inc
|
2.27 | 17.12M | 0 | -19.92M | -20.51M | -4.2716 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biovie Inc Stock (BIVI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-07-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-15 | 개시 | B. Riley Securities | Buy |
Biovie Inc 주식(BIVI)의 최신 뉴스
BioVie Inc Warrant 2025-01.06.30 on BioVie Financial Disclosures & SEC Filings - TradingView
Price to earnings forward of BioVie Inc. – NASDAQ:BIVI - TradingView
Price to sales forward of BioVie Inc. – NASDAQ:BIVI - TradingView
Enterprise value to revenue forward of BioVie Inc. – NASDAQ:BIVI - TradingView
Enterprise value to EBITDA forward of BioVie Inc. – NASDAQ:BIVI - TradingView
Enterprise value to EBIT forward of BioVie Inc. – NASDAQ:BIVI - TradingView
BioVie Inc. Class A Financial Disclosures & SEC Filings - TradingView
[EFFECT] BIOVIE INC. SEC Filing - Stock Titan
BioVie Inc. Class A Actuals & Estimates (NASDAQ:BIVI) - TradingView
BIVI Q1 2026 Earnings: EPS Beats Estimates as Drug Development ProgressesEarnings Per Share - dars.gov.et
BioVie | 4: Statement of changes in beneficial ownership of securities-Officer DO CUONG V - Moomoo
BIVI Forecast — Price Target — Prediction for 2027 - TradingView
BioVie Inc (BIVI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Biovie Files To Offer Up To $300 Million In SecuritiesSEC Filing - TradingView
BioVie (NASDAQ: BIVI) files $300M shelf registration to sell securities - Stock Titan
BioVie Inc (BIVI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BioVie Inc (BIVI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BioVie Inc (BIVI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BioVie Inc (BIVI) Institutional Confidence - TradingKey
BioVie Inc (BIVI) Valuation: PE, PB & Fair Value Analysis - TradingKey
BioVie Inc (BIVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BioVie Inc (BIVI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BioVie Inc (BIVI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BIVI Q1 2026 Earnings: EPS Beat Driven by Lower-than-Expected Operating ExpensesAdjusted Earnings Analysis - newsline.com
BIVI Q1 2026 Earnings: Narrower Loss Than Expected as Pipeline Progress ContinuesEnergy Earnings Report - newsline.com
BIVI Q1 2026 Earnings: EPS Beat Amid Clinical Progress; Stock DeclinesShare Repurchase Impact - newsline.com
Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareh - GuruFocus
Law firm investigates BioVie officers for possible breach of duties to shareholders - Pluang
BioVie Inc. (BIVI) Q1 2026 Earnings: EPS Surpasses Estimates Despite Ongoing Revenue VoidEarnings Call Highlights - newsline.com
BIVI Q1 2026 Earnings: Narrower-Than-Expected Loss but Stock Declines on No Revenue StreamTrough Earnings Signal - newsline.com
Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Barchart.com
Is BioVie's Bezisterim Poised for a Breakthrough in Neurodegenerative Diseases - Kavout | AI
BIVI: Imminent clinical data for Parkinson's and long COVID could unlock major commercial opportunities - TradingView
BioVie Deadline Alert - TMX Newsfile
BioVie Inc. Warrant (BIVIW) Holds Steady Near Support – Waiting for a CatalystNegative Gamma - dars.gov.et
BIVI Q1 2026 Earnings: Narrower Loss than Expected as Clinical Pipeline AdvancesTrough Earnings Signal - newsline.com
BioVie: Long COVID trial fully enrolled – ICYMI - Yahoo Finance
Foremost Clean Energy and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
BioVie Inc. (BIVI) Hovers Near Key Support Levels as Stock Remains FlatAdvance Decline Line - The Legal Advocate
Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2 - Weekly Voice
BioVie to highlight neuro and liver disease programs in June 2 investor webinar - Proactive financial news
BioVie Inc. (BIVI) Declines 5.26%, Testing Key Support Near $1.37Dealer Gamma - The Legal Advocate
BioVie Inc. (BIVI) Declines 5.26%, Testing Critical Support Near $1.37BPI Bear Confirmed - The Legal Advocate
BIVI Q1 2026 Earnings: EPS Beats Estimates Despite No Revenue, Stock DropsEstimate Accuracy - The Legal Advocate
Small cap wrap: First Phosphate, Miivo Holdings, 1911 Gold, BioVie… - Proactive financial news
BioVie completes enrollment in Long COVID trial as need for treatments grows - Proactive financial news
BioVie Inc. (BIVI) Faces Selling Pressure as Shares Slide 5.9%Momentum Trade - The Legal Advocate
BioVie (BIVI) Completes Enrollment for Phase 2 Trial of Bezister - GuruFocus
BioVie completes enrollment in Phase 2 Long COVID trial - Yahoo! Finance Canada
BioVie completes enrollment in Long COVID treatment trial - Investing.com
Biovie Inc (BIVI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):